OROrion Oyj ORINY · OTC
$53.25 +4.56% (+$2.32)
- Market cap
- 24.8B €
- Enterprise value
- 24.8B €
- P/E
- 42.2x
- Forward P/E
- 19.2x
- PEG
- 1.1x
- P/S
- 12.1x
- P/FCF
- 64.4x
- EV/EBITDA
- 31.6x
- ROIC
- 40.6%
- Gross margin
- 65.9%
- Net margin
- 28.5%
- Dividend yield
- 2.07%
- Payout ratio
- 87.2%
- Net debt/EBITDA
- 0.0x
- Beta
- 0.29
- Free float
- 44.0%
About the company
Orion Oyj is a Finnish pharmaceutical company headquartered in Espoo, focused on the research, development, manufacturing, and distribution of medicines and healthcare products. The company specializes in treatments for neurological and respiratory diseases, oncology, and urological disorders, while also offering a wide range of generic medicines and veterinary products. Orion operates not only in Finland but also internationally, in collaboration with various global partners. The company is recognized for its long-standing scientific heritage, high-quality standards, and strong focus on innovations that enhance patients’ quality of life.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Aino Anna Liisa Hurme
Employees
4,029
Headquarters
Espoo
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number